Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）

NCT01924195 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

117

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Anlotinib
DRUG: Placebo capsule

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.